Non-toxigenic Clostridium difficile: Phase I data

In a dose-escalation, placebo-controlled, Swiss Phase I trial in healthy volunteers ages 18-45 and 60 and up, single- and multiple-ascending doses of oral VP20621 were well tolerated with no serious o...